AbCellera Biologics (ABCL) PT Lowered to $38 at Berenberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts ABCL Hot Sheet
Price: $11.60 -5.54%
Rating Summary:
14 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
14 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Berenberg analyst Gaurav Goparaju lowered the price target on AbCellera Biologics (NASDAQ: ABCL) to $38.00 (from $43.00) while maintaining a Buy rating.
You May Also Be Interested In
- Modine Manufacturing (MOD) PT Lowered to $178 at Cantor Fitzgerald
- Arm Holdings (ARM) PT Lowered to $250 at TD Cowen
- Novo Nordisk (NVO) PT Raised to $44 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
